Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.47 USD | +0.61% | -3.16% | +0.23% |
Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.23% | 575M | |
-3.39% | 102B | |
+2.61% | 96.84B | |
-1.02% | 21.48B | |
-18.14% | 20.82B | |
-6.87% | 18.6B | |
-40.70% | 16.81B | |
-26.89% | 13.78B | |
+1.12% | 13.4B | |
+22.25% | 11.06B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio : Receives FDA's Accelerated Approval for Second Indication of GlaxoSmithKline's Jemperli